Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 20MEQ K versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 20MEQ K versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose is a monosaccharide that provides metabolic energy via glycolysis and the Krebs cycle, replenishing extracellular fluid glucose. Sodium and chloride are major extracellular electrolytes that maintain osmotic pressure and fluid balance; chloride serves as a counterion for acid-base regulation. Potassium is the primary intracellular cation essential for membrane potential, nerve impulse transmission, and muscle contraction. The solution provides water, electrolytes, and calories to correct fluid, electrolyte, and caloric deficits.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion; dose depends on fluid, electrolyte, and caloric needs. Typical adult dose: 1000-2000 mL/day, administered at 100-200 mL/hour. Potassium replacement: 20 mEq/L of solution, infused at a rate not exceeding 10 mEq/hour, with a maximum daily dose of 200 mEq.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Glucose: 1.5-2 h; potassium: 8-12 h; sodium: 12-24 h; clinical context: half-life affected by renal function and total body stores.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: glucose <0.5% excreted unchanged; sodium and potassium >90% reabsorbed; chloride follows sodium. Biliary/fecal: negligible.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte